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Serologic parameters of kala-azar were evaluated by Western blot analysis. Sera from kala-azar patients
with confirmed diagnoses were screened for immunoglobulin G (IgG) and IgG subclass-specific reactivity
against Leishmania donovani membrane antigen (LAg). Heterogenous LAg-specific IgG reactivity with numer-
ous proteins with molecular masses ranging from 18 to 190 kDa was observed. Though the individual band
patterns were varied, seven polypeptides of approximately 31, 34, 51, 63, 72, 91, and 120 kDa were immuno-
reactive with all the sera tested from kala-azar patients. The band patterns of the immunoblots of sera from
patients after treatment and clinical cure with sodium antimony gluconate revealed a decrease in the frequency
of the bands. Still, recognition of the 63- and 120-kDa bands was 100%, and the 55- and 91-kDa fractions were
recognized in 93% of the sera from cured individuals. Among the IgG subclasses, IgG1 reacted with the greatest
number of polypeptides. The 63-kDa protein was again detected by all of the IgG subclasses of all the sera
tested. Other fractions recognized by the subclasses of more than 70% of the serum samples included those of
47, 51, 55, and 78 kDa. Following treatment, 63- and 51-kDa bands were the most reactive with the IgG
subclasses. LAg-associated cross-reaction with other reference human antisera revealed a mild reactivity of the
63-kDa polypeptide with some of the serum samples from leprosy, malaria, typhoid, tuberculosis, and healthy
controls. Western blot analysis of LAg entrapped in liposomes, strong vaccine candidates against experimental
visceral leishmaniasis, revealed a more restricted band pattern. The 63-kDa fraction revealed by all pre- and
posttreatment sera showed almost negligible levels of cross-reaction with sera from patients with other diseases
or from healthy controls. These observations provide insight into induced immunity during kala-azar infection
for future application.
Protozoan parasites of the genus Leishmania cause a spec-
trum of diseases in humans. Cutaneous leishmaniasis is caused
by a wide range of species, including Leishmania major and
Leishmania tropica in the Old World and Leishmania mexi-
cana, Leishmania braziliensis, and Leishmania amazonensis in
the New World. These species cause a form of leishmaniasis
characterized by skin lesions rich in parasites, which are usually
localized and heal spontaneously. Active visceral leishmaniasis
(VL) caused by members of the Leishmania donovani complex,
including L. donovani donovani, L. donovani infantum, and L.
donovani chagasi, is characterized by fever, cachexia, hepato-
splenomegaly, and blood cytopenia and is usually fatal without
specific chemotherapy. L. donovani infections in humans, how-
ever, do not always result in VL. In areas were VL is endemic,
a significant population of individuals has a self-resolving in-
fection detectable only by the development of specific antibod-
ies and/or a T-cell response to leishmanial antigens (18, 35,
56). Furthermore, patients who have recovered from kala-azar
are usually immune to reinfection (25, 40). The resistance to
disease in these individuals is therefore met by an appropriate
host response, possibly through Leishmania antigens, for the
stimulation of protective responses in immune hosts. However,
the nature of the parasite antigens involved in eliciting this
immunity is not known.
The development of vaccines is the essential aim of studies
of leishmaniasis. Current research to understand the varied
aspects of regulation in the immune system is focused on the
immunopathology of leishmanial infections. Extensive studies
of experimental infections of L. major demonstrate the differ-
ential activation of CD4-T-helper-cell subsets with the pre-
dominance of Th1 (interleukin-2 [IL-2] and gamma interferon
[IFN-]) in resistant C3H and C57BL/6 mice and an exclusive
Th2-dominant response (IL-4 and IL-5) in susceptible BALB/c
mice (2, 26, 27, 47). The immunology of VL, even in the
murine system, is not well defined. Studies of mice infected
with L. donovani show no evidence of the production of CD4-
Th2-cell-restricted cytokines with the progression of infection.
On the contrary, Th1- and Th2-cell-associated cytokines have
been reported for experimental VL (32, 43). In human infec-
tions with L. donovani, a marked depression in the T-cell
response is characterized by the absence of IL-2 and IFN-
production in vitro (13, 16, 56). Studies of tissue cytokine
mRNA expression demonstrate a role for IL-10 in downregu-
lating T-cell immune responses as well as an association be-
tween increased IL-10 production and the pathology seen in L.
donovani infections (22, 34). However, active VL is also cor-
related with enhanced induction of lesional IFN- and IL-2
together with IL-10 and/or IL-4 and elevated levels of IFN-,
IL-4, IL-10, and immunoglobulin E (IgE) in serum (31, 34, 61,
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65). After successful treatment, the presence of IFN-, IL-4,
and IL-10 in vitro and in vivo suggests the coexistence of Th1
and Th2 in kala-azar patients as well as in cured individuals
(11, 15, 33, 34). Thus, despite the impressive recent advances in
understanding the cell-mediated immune responses of these
infections, it is still difficult to delineate the responses leading
either to visceral disease or to protective immunity.
Kala-azar is also characterized by strong antibody titers.
Cytokines elaborated by activated T cells induce the switching
of B lymphocytes to several IgG isotypes and are thus obliga-
tory for some humoral responses. IFN-, the Th1 cytokine,
upregulates the isotypes IgG2a and IgG3 in mice and probably
IgG1 and IgG3 in humans. IL-4 and IL-5, Th2 cytokines, stim-
ulate the production of high levels of IgM, IgE, and IgG iso-
types such as IgG1 in mice and IgG4 in humans (1, 52). Anal-
ysis of Leishmania antigen-specific Ig isotypes and IgG
subclasses in VL patient sera revealed elevated levels of IgG,
IgM, IgE, and IgG subclasses during disease (7, 10, 17, 55).
Drug resistance was associated with a reduction in IgG2 and
IgG3 antibodies, with no significant change in the titers of IgG,
IgM, IgA, IgE, and IgG4. A marked elevation, however, of
IgG1 antibodies was observed in all these patients (8). A suc-
cessful cure corresponded with a decline, most significantly, in
the levels of IgE, IgG4, and IgG1 (8, 10, 17). The differential
patterns of Ig isotypes observed during disease, drug resis-
tance, and cure were specific for antigens of L. donovani. The
L. donovani promastigote membrane antigens (LAg) used in
our laboratory (8) also demonstrate a strong vaccine potenti-
ality alone, and in association with liposomes, for experimental
VL (3, 5). The purpose of this study was to dissect the humoral
immune responses to the components of LAg in kala-azar
patients by Western blot analysis. The recognition of the an-
tigens by IgG and its subclasses before and after chemotherapy
provides insight into the immunity induced by this pathogen.
Analysis of LAg in liposomes with pre- and posttreatment IgG
antibodies demonstrates the diagnostic and prognostic poten-
tiality of this preparation for kala-azar.
MATERIALS AND METHODS
Study subjects. The subjects of the longitudinal study of the present investi-
gation consisted of 15 VL patients, 7 to 48 years old, from Bihar and West Bengal
(Eastern India), the main areas of endemicity. This group, comprised of 5 women
and 10 men, was admitted to the School of Tropical Medicine, Calcutta, India.
A diagnosis of VL was based upon a set of collective elements: the presence of
parasites in bone marrow and/or spleen aspirates, epidemiological history, and
response to specific treatment. Each of the 15 patients included in the study was
sampled for serum twice, on day 0, i.e., before initiation of therapy, and 50 days
after successful treatment with 20 injections of 20 mg of sodium antimony
gluconate (SAG) per kg of body weight. The 15 individuals included as controls
were from Calcutta, a region where VL is not endemic, with no previous history
of kala-azar. This group consisted of three malaria patients, three typhoid pa-
tients, three tuberculosis patients, three leprosy patients, and three healthy
controls from the Indian Institute of Chemical Biology (IICB). The endemic
diseases were confirmed bacteriologically in the cases of typhoid, tuberculosis,
and leprosy and parasitologically in the case of malaria, and sera were collected
before treatment. Sera were obtained by venipuncture from patients and con-
trols. Blood was allowed to coagulate at room temperature and then centrifuged
at 1,400  g for 10 min. All sera were stored at 20°C until use. The study was
approved by the Ethical Committee on Human Subjects, IICB. Informed consent
was obtained from all patients for blood sampling.
Preparation of L. donovani antigen. L. donovani antigen AG83, originally
isolated from an Indian kala-azar patient, was cultured in vitro for antigen
preparation as described earlier (3). Briefly, stationary-phase promastigotes,
harvested after the third or fourth passage, were washed four times in cold
phosphate-buffered saline, pH 7.2 (PBS), and resuspended at a concentration of
1.0 g of cell pellet in 50 ml of cold 5 mM Tris-HCl buffer, pH 7.6. The suspension
was vortexed six times for 2 min each, with a 10-min interval of cooling on ice
between each vortexing. The parasite suspension was then centrifuged at 2,310
g for 10 min. The crude ghost membrane pellet thus obtained (42) was resus-
pended in the same Tris buffer and sonicated three times for 1 min each at 4°C
in an ultrasonicator. The suspension was finally centrifuged at 5,190  g for 30
min, and the supernatant containing the LAg was harvested and stored at 70°C
until use. The amount of protein obtained from a 1.0-g cell pellet, as assayed by
the method of Lowry et al. (39), was approximately 16 mg.
Electroelution of proteins with 63- and 72-kDa bands by SDS-PAGE. Proteins
with molecular masses of 63 and 72 kDa were eluted from leishmanial antigens
(LAg) of L. donovani promastigotes subjected to sodium dodecyl sulfate–10%
polyacrylamide gel electrophoresis (SDS–10% PAGE) as described earlier (4).
Proteins with molecular masses of 63 (gp63) and 72 kDa were localized in gels,
stained with Coomassie blue, and eluted by electrophoresis in running buffer
(0.025 M Tris, 0.192 M glycine, 1% SDS) at 10 mA for 5 h. After elution, the
proteins were dialyzed, lyophilized, and resuspended in PBS.
Preparation of liposomes. Positively charged liposomes were prepared with
egg lecithin, cholesterol, and stearylamine at a molar ratio of 7:2:2 as reported
previously (3). The thin, dry film consisting of the lipid mixture was dispersed in
PBS for the preparation of empty liposomes. Vesicles with entrapped leishmanial
antigen were prepared by the dispersion of the lipid film in PBS containing 1 mg
of LAg per ml. The mixture was vortexed, and the suspension was sonicated for
30 s in an ultrasonicator. Liposomes with entrapped antigen were separated from
the excess free antigen by three successive washings in PBS with centrifugation
(105,000  g for 60 min at 4°C). The protein content entrapped in liposomes was
estimated by using bovine serum albumin as the standard in the presence of 1%
SDS and appropriate blanks (39). The average amount of LAg associated per
milligram of egg lecithin was 35 g. Similarly, electroleluted 63- and 72-kDa
polypeptides were entrapped in positively charged liposomes. The lipid film was
dispersed in 1 ml of PBS containing 350 g of protein, and 4.5 g of the 63-kDa
polypeptide and 3.5 g of the 72-kDa polypeptide were associated with 1 mg of
egg lecithin.
Protein electrophoresis and immunoblot analysis. The leishmanial antigens
were subjected to SDS–10% PAGE under standard conditions (36) in a Mini-
Protean system (Bio-Rad Laboratories, Richmond, Calif.). Proteins free in PBS
or entrapped in liposomes (6 g per lane) separated on the gel were silver
stained (64).
For immunoblot analysis, the resolved proteins were electrophoretically trans-
ferred to nitrocellulose membranes (Schleicher & Schuell, Dassel, Germany),
and the assays were performed according to the method of Rolland-Burger et al.
(51), with slight modifications. The nitrocellulose strips were blocked overnight
in 100 mM Tris-buffered saline, pH 7.6 (TBS), containing 0.1% Tween 20 (T-20),
washed once with 0.05% T-20 in TBS (washing buffer), and incubated for 1 h
with human sera. All sera, including those from acute- and convalescent-phase
kala-azar patients as well as sera from positive controls (patients with malaria,
tuberculosis, typhoid, and leprosy) and negative controls (healthy personnel of
the Institute who were not from areas of endemicity), were diluted 1:100 in
washing buffer. For reactivity with electroeluted polypeptides, 1 g of liposomal
antigen per lane was subjected to SDS–10% PAGE, transferred to nitrocellulose
membranes, and probed with kala-azar patient sera as described above. The blots
were then washed three times for 20 min each and incubated again for 1 h with
a 1:1,000 dilution of peroxidase-conjugated anti-human IgG (Sigma Immuno-
chemicals, St. Louis, Mo.), followed by three washes as described above. For IgG
subclass reactivity, the incubation of the membranes with human sera at a 1:100
dilution was followed by a 1-h reaction with anti-human IgG1, IgG2, IgG3, and
IgG4 monoclonal antibodies (1:300 dilution; Sigma Immunochemicals). After
being washed, the blots were reacted again for 1 h with a 1:500 dilution of
peroxidase-conjugated goat anti-mouse IgG (Sigma Immunochemicals) and
washed as before except for the last wash, which was done without T-20. Enzy-
matic activity was revealed with 15 mg of 3,3-diaminobenzidine tetrahydrochlo-
ride (Sigma Immunochemicals) in 30 ml of TBS containing 15 l of 30% H2O2.
The efficacy of transfer of leishmanial proteins was regularly checked and con-
firmed by concurrent gel staining with Coomassie blue or silver and nitrocellu-
lose membrane staining with 0.1% Ponceau S in 1% acetic acid. Following
staining, the parts of the membrane containing molecular mass standards were
marked with ink.
RESULTS
Study subjects. The clinical and laboratory features of kala-
azar patients studied herein are summarized in Table 1. The
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characteristic symptom of fever was observed in all patients on
admission. Interestingly, three out of five patients from West
Bengal also exhibited bilateral epitrochlear lymphoadenopa-
thy. All patients responded to SAG therapy, and no parasites
were found in the splenic aspirates at the end of treatment.
Antigen profile of LAg and LAg-liposome. LAg, alone or in
association with positively charged liposomes, was fractioned
by SDS–10% PAGE (Fig. 1). Free LAg (lane 1) comprised
approximately 35 polypeptides ranging in molecular mass from
18 to 190 kDa, with distinct polypeptides at 18, 22, 27, 31, 34,
39, 43, 45, 47, 51, 55, 63, 72, 78, 91, 97, 110, 120, and 145 kDa.
LAg entrapped in positively charged liposomes (lane 2) com-
prised approximately 17 polypeptides in the range of 18 to 145
kDa. Although a large number of polypeptides of LAg were
incorporated in the liposomes, a mechanism of selective en-
trapment for some polypeptides was observed. Furthermore,
comparison of a similar concentration of protein (6 g) in free
LAg and LAg entrapped in liposomes revealed that although a
number of polypeptides stained with almost equal intensities in
LAg, a duplex of 61 to 66 kDa stained most intensely in lipo-
some-associated LAg (lane 2), demonstrating a preferential
entrapment of this polypeptide by the liposome.
IgG-specific reactivity of LAg with VL-infected sera, before
and after chemotherapy. The sera from 15 VL-infected pa-
tients were tested for IgG reactivity to SDS-PAGE-separated
polypeptides of LAg blotted onto nitrocellulose. The response
of IgG, the predominant Ig class in VL-infected patient sera (7,
20), to L. donovani LAg polypeptides revealed specific recog-
nition of polypeptides ranging from 18 to 190 kDa (Fig. 2).
Binding patterns exhibited variability depending on individual
serum reactivity. Despite heterogenous reactivity to LAg,
seven polypeptides corresponding to relative molecular masses
of 31, 34, 51, 63, 72, 91, and 120 kDa were reactive with all of
the 15 sera from kala-azar patients prior to treatment. In
addition, major bands of 55, 78, and 145 kDa (93%); 36 and 39
kDa (80%); 97 kDa (73%); 18 and 47 kDa (60%); and 20 and
43 kDa (40%) were recognized most frequently (Fig. 2A).
With successful treatment with SAG, decreases in the fre-
quency of recognition and in the intensities of bands were
FIG. 1. Silver-stained SDS-PAGE gel of Leishmania antigens and
liposomes. Lanes: 1, LAg; 2, LAg-liposome. The positions of promi-
nent bands are shown on the left at apparent molecular masses in
kilodaltons.
FIG. 2. Western blot analysis of kala-azar serum IgG reactivity with
SDS-PAGE-separated (6-g) membrane proteins of LAg before
(A) and after (B) SAG treatment. Each lane represents one VL pa-
tient, and longitudinal samples have identical lane numbers. The ap-
parent molecular masses of prominent bands in kilodaltons are
marked on the left.
TABLE 1. Clinical and laboratory features of kala-azar patients
Characteristic
Study group
Pretreatment Posttreatment
No. of patients 15 15
Age (yr) 22.53  3.16
Weight (kg) 34.80  2.48 36.60  2.48
Duration of illness (mo) 3.83  0.30
Karnofsky scorea 76.53  1.33 83.66  1.06
Splenic size (cm) 10.72  1.06 6.57  0.99
Splenic aspirate scoreb 4.07  0.18 Negative
Leukocyte count (103/mm3) 3.48  0.15 4.11  0.15
Hemoglobin concn (g/dl) 5.30  0.29 7.30  0.21
Platelet count (103/mm3) 0.71  0.02 0.75  0.03
Liver function test
Total protein (g/dl) 8.51  0.30 8.28  0.30
Albumin (g/dl) 3.17  0.12 3.59  0.13
Globulin (g/dl) 5.37  0.32 4.66  0.36
a The Karnofsky performance scale is as follows: 100, normal, no complaints,
no evidence of disease; 90, able to carry on normal activity, minor symptoms of
disease; 80, normal activity with effort, some symptoms of disease; 70, cares for
self, unable to carry on normal activity or active work.
b 5,  10 to 100 parasites/field; 4, 1 to 10 parasites/field; 3, 1 to 10
parasites/10 fields; 2, 1 to 10 parasites/100 fields; 1, 1 to 10 parasites/1,000
fields; 0, no parasites or 1 to 10 parasites/1,000 fields.
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observed. Some fractions, such as those with bands at 36, 43,
47, 51, 97, and 145 kDa, showed strong reactivity with a large
number of VL-infected-patient sera and reacted with a smaller
number of sera after treatment (Fig. 2B). However, fractions
such as those with bands of 55 and 91 kDa (93%); 34, 72, and
78 kDa (87%); and 31 kDa (73%) were still reactive with
posttreatment sera with high frequencies, and two bands of 63
and 120 kDa were observed in all sera after cure.
Antibody-type reactivity. Western blot analysis of kala-azar
serum reactivity against L. donovani antigen indicates a strong
IgG reaction against the different polypeptides of LAg, before
and after chemotherapy (Fig. 2). To determine which human
subclasses of IgG were responsible for these interactions,
Western blot assays specific for IgG1, IgG2, IgG3, and IgG4
were performed with seven sera from kala-azar patients in our
longitudinal study, and data from four patients are presented
in Fig. 3 (lanes 1, before treatment; lanes 2, following success-
ful cure with SAG). All subclasses of IgG were reactive with
the polypeptides of LAg, demonstrating multiband patterns of
various frequencies. The most prominent reaction was ob-
served with IgG1 (71 to 100% of the sera recognizing polypep-
tides of 18, 34, 39, 43, 47, 51, 55, 63, 72, 78, 91, and 120 kDa),
followed by IgG3 (39, 47, 51, 55, 63, 78, and 91 kDa), IgG2 (34,
47, 51, 55, 63, 72, 78, and 91 kDa), and IgG4 (39, 47, 51, 55, 63,
72, 78, and 91 kDa). Immunoblot banding patterns with anti-
IgG1 closely resembled those produced with anti-IgG, suggest-
ing that IgG1 is the dominant IgG subclass induced during
disease. Despite the reported fall in the IgG subclass antibody
titers following treatment (8, 17), there was persistent recog-
nition of the polypeptides of LAg through all of the subclasses.
However, while the reactivity of IgG2, IgG3, and IgG4 was
limited to two to four bands of 47, 51, 55, and 63 kDa, IgG1
demonstrated a pattern of reduced intensity that was almost
identical to that prior to treatment.
Serologic reactivity with normal sera and other pathogens.
In order to assess the degree of cross-reactivity of the antigens
of L. donovani with normal sera and sera from patients with
other tropical diseases coendemic with kala-azar, LAg blots
were probed with various control sera (Fig. 4). While most of
the polypeptides of LAg did not show reactivity with control
FIG. 3. Immunoblot profiles of LAg-specific IgG subclass reactivities of four (A to D) kala-azar patients before and after SAG treatment. Lanes
1, pretreatment sera; lanes 2, posttreatment sera. The positions of prominent bands at apparent molecular masses in kilodaltons are shown on the
left.
FIG. 4. Western blot analysis of IgGs of various sera for reactivity
to LAg. Lanes 1 to 3, sera from malaria patients; lanes 4 to 6, sera from
typhoid patients; lanes 7 to 9, sera from tuberculosis patients; lanes 10
to 12, sera from leprosy patients; lanes 13 to 15, sera from healthy
subjects. The position of the major band (in kilodaltons) is indicated
on the left.
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sera, samples used in this assay demonstrated cross-reaction of
low intensity with the 63-kDa protein in 73% of the sera.
Immunoblot analysis of the LAg-liposome for IgG. All the
sera from 15 VL patients, before and after SAG treatment, and
15 control sera were further studied for IgG reaction with L.
donovani antigens entrapped in liposomes. Pretreatment sera
recognized 11 polypeptides of LAg in liposomes, correspond-
ing to relative molecular masses of 31, 34, 47, 51, 63, 72, 78, 95,
97, 110, and 145 kDa (Fig. 5A). The patterns of response
varied in the different sera tested. However, maximum reac-
tivity was observed for the 51- and 63-kDa polypeptides, which
were recognized by all sera, followed by the 47-kDa (87% of
sera); 72-, 78-, and 97-kDa (73%); and 34-kDa (60%) polypep-
tides. Posttreatment sera reacted with only three polypeptides
(47, 63, and 97 kDa) (Fig. 5B), with 100% recognition for the
63-kDa polypeptide. No cross-reactivity with any polypeptide
of LAg in liposome was observed with positive-control (sub-
jects with malaria, typhoid, tuberculosis, and leprosy) as well as
with negative-control (healthy subjects) sera (Fig. 5C), dem-
onstrating the 100% specificity of this assay. Recognition of
polypeptides such as those of 51 kDa (100% of sera) and 72
and 78 kDa (73% of sera) by a high proportion of pretreatment
sera and the loss of reactivity of these antigens by all posttreat-
ment sera tested suggest that these polypeptides in liposomes
can help discriminate sera positive for disease not only from
control but also from posttreatment sera from cured individ-
uals. Polypeptides with masses of 63 and 72 kDa were electro-
eluted by SDS-PAGE and entrapped in liposomes. Whereas
the 63-kDa protein showed reactivity with both infected sera
and sera from cured individuals (data from results with one of
the five sera are shown), reaction with the 72-kDa protein was
restricted to disease sera only (Fig. 6).
DISCUSSION
It is well established that infection with L. donovani and its
control are mediated through the activities of Th1- and Th2-
cell-associated cytokines. Successful treatment of VL patients
generally results in resistance to reinfection, suggesting a re-
direction of polarized responses in the host. However, protec-
tion has often been found to be associated with both Th1 and
Th2 responses (12, 22, 28, 34, 46, 61, 65). Moreover, determin-
ing the Th1 or Th2 nature of human immune responses is often
problematic. On the other hand, analysis of the relative abun-
dances of pathogen-specific antibodies reveals a distinct pat-
tern of Ig isotypes and IgG subclasses during disease, resis-
tance to treatment, and cure (7, 8, 17, 24). While the types of
Igs produced, including different subtypes and subclasses, are
regulated by the cytokine environment, elicitation of these
immunoglobulins is Leishmania antigen specific. Hence, the
identification of antigens involved in inducing these responses
is of critical importance.
A mixture of LAg, potential vaccine candidates against ex-
perimental VL, shows strong reactivity with Indian kala-azar
patient sera (7, 8). Attempts to identify the components of LAg
recognized by the VL patient sera in immunoblot experiments
showed variations in the patterns of antigen recognition by the
different sera from infected patients. However, the specificity
of IgG antibody for seven polypeptides of LAg, including the
63-kDa polypeptide, observed in all patients demonstrates the
consistency of the banding pattern within the clinical manifes-
tations. The 63- to 65-kDa polypeptide, or gp63 (4), recognized
prominently by human VL sera (9, 37, 57), has been proposed
FIG. 5. Western blot analysis of the serum IgG reactivities of 15
sera from kala-azar patients in our longitudinal study, with LAg being
incorporated into liposomes following separation by SDS-PAGE.
(A) Reactivity with acute-phase sera; (B) corresponding reactivity af-
ter SAG treatment; (C) cross-reactivity with serum from patients with
malaria (lanes 1 to 3), typhoid (lanes 4 to 6), tuberculosis (lanes 7 to 9),
and leprosy (lanes 10 to 12) and healthy controls (lanes 13 to 15). The
major bands (in kilodaltons) are marked on the left.
FIG. 6. Western blot analysis of liposomal 63- and 72-kDa anti-
gens. Polypeptides of 63 kDa (lanes 1 and 2) and 72 kDa (lanes 3 to
12), purified by electroelution, were incorporated into liposomes and
probed with kala-azar patient sera before (odd-numbered lanes) and
after (even-numbered lanes) SAG treatment.
VOL. 72, 2004 HUMORAL ISOTYPE IMMUNITY TO VL 867
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as a candidate antigen in the immunodiagnosis of leishmaniasis
(45, 49, 59). Apart from gp63, antigens specifically recognized
by VL patient sera have been identified as gp70-2 and dp72
(29). Reactivity with crude parasite antigen demonstrated that
90% of the patients with VL produced antibodies to these
proteins. Although the identity of the 72-kDa protein observed
in our studies has not been proved to be dp72, its molecular
mass and the extent of its immunogenicity point to a similarity
with dp72. It is of interest that while the 72-kDa polypeptide of
LAg reacted with 100% of the Indian kala-azar patient sera
tested, this level of sensitivity could not be attained even with
the pure dp72 (93%). The other polypeptides of LAg recog-
nized by all VL patient sera include those of 31, 34, 51, 91, and
120 kDa. While strict comparisons between our results and
those reported in the literature are difficult due to the use of
different strains and antigens, the immunodominant 31- and
34-kDa bands of LAg characterized in the present study ap-
pear to correspond to the p32, and 32- to 35-kDa, membrane-
associated antigens and whole-parasite extracts of L. donovani
infantum and L. donovani chagasi reported by other investiga-
tors (21, 48, 62). Further, the reactivity of the 120-kDa
polypeptide in our study finds similarity with the 119-kDa
polypeptide from L. donovani chagasi and L. donovani infan-
tum reacting with all VL patient sera (19, 51).
The differences between the pre- and posttreatment sera
were a decrease in the reactivity and intensity of most of the
polypeptides and the disappearance of a few bands. A number
of polypeptides, however, persisted in a large number of cured
individuals. Two polypeptides, with molecular masses of 63
and 120 kDa, which were recognized by all pretreatment sera,
were also reactive with all posttreatment sera. The reactivity of
the 63-kDa band with sera from cured individuals is contra-
dictory to what was observed with native gp63, purified from a
Kenyan L. donovani isolate, which could distinguish between
ongoing and previous infection with L. donovani (45). The
antibody positivity may be due partly to the Western blot
technique used in our studies, which was more sensitive than
the enzyme-linked immunosorbent assay used by Okongo-
Odera et al. (45). A similar lack of change of specific band
patterns of pre- and posttreatment sera as determined by
Western blot analysis has been reported for the sera of indi-
vidual humans infected with L. donovani chagasi (48) and L.
donovani infantum (41). The presence of Leishmania antigen-
specific IgG antibodies, probably for years after clinical and
parasitological “cure,” indicates the persistence of a subclinical
infection in these individuals. While this state may cause a
reemergence of active disease under conditions of immune
suppression (6), complete elimination of Leishmania parasites
in an immunocompetent individual may result in the loss of
parasite-specific antibodies and susceptibility to reinfection
(63).
In this study, we further characterized the humoral immu-
nological response to the components of LAg by analyzing the
distribution of IgG subclass antibodies in the sera of VL pa-
tients. As the four antibody subclasses revealed differential
patterns in the sera of kala-azar patients after chemotherapy
(8, 17), analysis of the antigens with respect to their patterns of
reactivity to the different IgG subclasses may be further indic-
ative of disease activity and pathogenicity. Western blot anal-
ysis in the present study indicates that with pretreatment sera,
reaction to LAg as well as to total IgG appears to be maximally
related to the IgG1 isotype of IgG, although significant reac-
tion with IgG3 followed by IgG2 and IgG4 was also observed.
The IgG antibody titers present in the sera of VL patients were
predominantly of the IgG1 subclass (8, 24), and the high fre-
quency of IgG1 with the L. donovani antigens suggests a dom-
inance of IgG1 recognition. A number of investigators, how-
ever, have reported no correlation between antibody titer by
radioimmunoassay, enzyme-linked immunosorbent assay, or
indirect immunofluorescence and the intensity of the reaction
or the number of bands recognized by Western blotting (30, 41,
50). In accordance, a persistence of reactivity of IgG subclasses
determined by Western blot analysis was observed with post-
treatment sera despite the reported fall in their titers after cure
(8, 17), and the band pattern, especially of IgG1, was almost
identical to that of pretreatment sera. IgG1 and IgG3 are the
predominant IgG subclasses involved in functions such as at-
tachment to Fc receptors on cell membranes (opsonization;
primarily IgG1), mediation of antibody-dependent cellular cy-
totoxicity, and complement activation (primarily IgG3). The
significance of the relative abundances of these Leishmania-
specific antibodies during disease, and their persistence after
cure, is unclear since immunity to intracellular pathogens such
as Leishmania is controlled by cell-mediated effector mecha-
nisms, with humoral immunity apparently having little or no
role. A review of the literature, however, reveals considerable
evidence that antibody can mediate protection against many
viral and nonviral intracellular pathogens (14, 38). The recent
observation that specific antibodies and Fc receptors are cru-
cial for the development of an enhanced and effective Th1
response during Chlamydia reinfections (44) suggests a similar
participation of Leishmania-specific IgG1 antibodies in Fc re-
ceptor-mediated enhancement of the Th1 response for faster
and higher immune effectors for rapid clearing of reinfections.
The possible role of antibody-mediated protection against
Leishmania, though yet to be ascertained, signifies the impor-
tance of identification of antigens that may elicit protective
antibodies. The predominant recognition of the 63-kDa band
by all posttreatment kala-azar sera tested through most of the
IgG subclasses points to a potential role of gp63 in protection
against this disease. Attempts to analyze L. donovani antigens
through reactivity with IgG subclasses have been reported by
other researchers (23, 58). However, since those studies used a
soluble promastigote extract as the antigen for the Western
blot technique, it is difficult to compare our results with the
results published by those groups.
Serologically, cross-reactivity between Leishmania species
and other pathogens has been reported for whole-cell lysates
(19, 60). Analysis of components of LAg that were reactive to
antisera from patients with malaria, typhoid, tuberculosis, and
leprosy and to sera from healthy controls demonstrated varied
cross-reactivities in every case, including a mild reaction to
normal human sera with the 63-kDa polypeptide.
Investigation of the antigenic structure of LAg of L. dono-
vani is of fundamental importance for devising methodologies
that will allow for more specific immunodiagnosis and prog-
nosis for the development of successful vaccines. Leishmanial
antigens have been studied extensively in experimental models
for the development of vaccines. However, antigens protective
in the murine host may not elicit immune responses in humans
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(54), emphasizing the importance of testing leishmanial anti-
gens with human cells and sera. LAg, in association with lipo-
somes, have been found to be strong vaccine candidates against
experimental VL (3, 5). Since maximum protection was ob-
served with LAg in positively charged liposomes (3), this an-
tigen preparation was investigated for reactivity with sera from
pre- and posttreatment kala-azar patients. Although a large
number of polypeptides of LAg were associated with the lipo-
somes, the preferential entrapment of some proteins by these
liposomes, including proteins of 63 kDa, has been observed
(Fig. 1 and 4). The reaction with the infected-patient sera
revealed this difference, and the pattern of bands recognized
with LAg-liposomes was limited compared to that with LAg
alone (Table 2). The absence of cross-reactions between the
sera from individuals with any other disease and the polypep-
tides in liposomes demonstrates that antibody reaction with
LAg in liposomes is highly specific. This finding was again
evident when LAg-liposomes were probed with sera obtained
after treatment. Only the antibodies with high specificities ap-
peared to react with the polypeptides (43, 63, and 97 kDa) in
LAg-liposomes. The appearance of a 63-kDa band in all sera
tested suggests the persistence of high-affinity anti-gp63 anti-
bodies in cured kala-azar patients. Since gp63 is the major
glycoprotein involved in the uptake of the parasites by macro-
phages (53), the persistence of anti-gp63 antibodies in all kala-
azar patients after cure suggests that these antibodies may have
an important role in life-long immunity generally observed in
successfully cured individuals. The loss of reactivity of proteins
such as those of 51, 72, and 78 kDa, which were recognized in
high frequencies by patient sera, after treatment may help
discriminate between active and cured disease. The specific
reactivity of the electroeluted 72-kDa polypeptide in liposomes
with infected kala-azar patient sera suggests the potential sen-
sitivity and specificity of these polypeptides in liposomes for
diagnosis, and their lack of reactivity after successful cure may
be a powerful tool for the management of kala-azar.
Continued progress in the immune characterization of VL is
critical in our efforts to decipher the complex nature of L.
donovani infections for application in diagnosis, prognosis, and
vaccine development.
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